Literature DB >> 28696719

An Insight into Glyco-Microheterogeneity of Plasma von Willebrand Factor by Mass Spectrometry.

Ebtesam A Gashash1,2, Arya Aloor1, Dong Li3, He Zhu1, Xiao-Qian Xu4, Cong Xiao1, Junping Zhang5, Aishwarya Parameswaran1, Jing Song1, Cheng Ma1, Weidong Xiao5, Peng George Wang1.   

Abstract

Human plasma von Willebrand Factor (VWF) plays essential roles in primary hemostasis in cooperation with other coagulations factors. There is ample indication that glycosylation affects many biological phases during the protein life cycle. However, comprehensive characterization of all probable N-glycosites simultaneous with O-glycosites is still not fully revealed. Thus, the intention of this exploration was to estimate the occupancy of all canonical N-glycosites besides simultaneous characterization of N- and O-glycoforms. An RP-LC-MS/MS system functionalized with CID and HCD tandem mass was utilized to analyze VWF. N-Glycosite occupancy varied along the protein backbone chain. Out of 257 HCD spectra, 181 characterized glycoforms were specified as either N- or O-glycosites. Sequential cleavage of glycosidic bonds along with Human Database mass matching have confirmed the glycoform structures. A total of 173 glycoforms represented most commonly biantennary and infrequently tri- and tetra-antennary N-glycans beside high mannose, hybrid, ABH antigen-terminated, and sulfated N-glycans. Many glycoforms were common across all N-sites. Noteworthy, previously unreported N-glycosites within domain D'(TIL'-E') showed glycosylation. Moreover, sialylated core 1 and core 2 O-glycans were detected on 2298T. Given subtle characterization of site-specific glycoforms, we can attain a profound understanding of the biological roles of VWF as well as facilitate the production of VWF-based therapeutics.

Entities:  

Keywords:  CID; HCD; N-glycan; O-glycan; VWF; glycosylation; mass spectrometry; microheterogeneity; occupancy; plasma von Willebrand Factor

Mesh:

Substances:

Year:  2017        PMID: 28696719      PMCID: PMC6309539          DOI: 10.1021/acs.jproteome.7b00359

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  55 in total

1.  Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging.

Authors:  Hiroyuki Kaji; Yoshio Yamauchi; Nobuhiro Takahashi; Toshiaki Isobe
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  pFind 2.0: a software package for peptide and protein identification via tandem mass spectrometry.

Authors:  Le-Heng Wang; De-Quan Li; Yan Fu; Hai-Peng Wang; Jing-Fen Zhang; Zuo-Fei Yuan; Rui-Xiang Sun; Rong Zeng; Si-Min He; Wen Gao
Journal:  Rapid Commun Mass Spectrom       Date:  2007       Impact factor: 2.419

3.  Universal sample preparation method for proteome analysis.

Authors:  Jacek R Wiśniewski; Alexandre Zougman; Nagarjuna Nagaraj; Matthias Mann
Journal:  Nat Methods       Date:  2009-04-19       Impact factor: 28.547

4.  Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures.

Authors:  T Matsui; K Titani; T Mizuochi
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

5.  Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis.

Authors:  James S O'Donnell; Thomas A J McKinnon; James T B Crawley; David A Lane; Michael A Laffan
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

Review 6.  ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

Authors:  P Vince Jenkins; James S O'Donnell
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

7.  N-linked glycosylation of VWF modulates its interaction with ADAMTS13.

Authors:  Thomas A J McKinnon; Alain C K Chion; Alexander J Millington; David A Lane; Mike A Laffan
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

8.  Analysis of protein glycosylation by mass spectrometry.

Authors:  Willy Morelle; Jean-Claude Michalski
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

9.  GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans.

Authors:  Alessio Ceroni; Kai Maass; Hildegard Geyer; Rudolf Geyer; Anne Dell; Stuart M Haslam
Journal:  J Proteome Res       Date:  2008-03-01       Impact factor: 4.466

Review 10.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

View more
  5 in total

1.  Comprehensive N- and O-glycosylation mapping of human coagulation factor V.

Authors:  Cheng Ma; Ding Liu; Dong Li; Junping Zhang; Xiao-Qian Xu; He Zhu; Xiu-Feng Wan; Carol H Miao; Barbara A Konkle; Philip Onigman; Weidong Xiao; Lei Li
Journal:  J Thromb Haemost       Date:  2020-06-14       Impact factor: 5.824

2.  Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients.

Authors:  Barbara Lunghi; Massimo Morfini; Nicola Martinelli; Silvia Linari; Giancarlo Castaman; Francesco Bernardi
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

Review 3.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

4.  Site-Specific N-Glycosylation on the AAV8 Capsid Protein.

Authors:  Arya Aloor; Junping Zhang; Ebtesam A Gashash; Aishwarya Parameswaran; Matthew Chrzanowski; Cheng Ma; Yong Diao; Peng George Wang; Weidong Xiao
Journal:  Viruses       Date:  2018-11-17       Impact factor: 5.048

5.  Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance.

Authors:  Soracha E Ward; Jamie M O'Sullivan; Alan B Moran; Daniel I R Spencer; Richard A Gardner; Jyotika Sharma; Judicael Fazavana; Marco Monopoli; Thomas A J McKinnon; Alain Chion; Sandra Haberichter; James S O'Donnell
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.